The human trial of COVID-19 vaccine candidate developed by the University of Oxford and backed by AstraZeneca Plc has shown a positive result. The researchers found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. Oxford’s vaccine is designed to reduce disease and transmission. Director at the Jenner Institute of Oxford University, Dr Adrian Hill, explains the mechanism of this vaccine “this vaccine triggers both arms of the immune system”.
As per the British Medical Journal Lancet:
The vaccine was officially known as AZD1222, prompted a protective immune response in hundreds of people who got the shot and did not prompt any serious side effects. According to trial results published in The Lancet medical journal, the Covid-19 vaccine prompted no serious side effects and elicited antibody and T-cell immune responses with the strongest response seen in people who received two doses.
About AZD1222 vaccine:
In an age where technology and finance intersect at lightning speed, Luana Lopes Lara, a…
In a significant development for higher education in India, Victoria University (VU) from Australia is…
Many lakes around the world are known by special names because of their stories, beauty,…
Under Section 45ZL of the Reserve Bank of India Act, 1934, every quarter, India’s Monetary…
India hosts nearly 8% of the world’s biodiversity, making conservation crucial for ecological balance and…
Swaraj Kaushal, the former Governor of Mizoram, a noted senior advocate, and the husband of…